Inactive Instrument

ReShape Lifesciences Inc. Stock Other OTC

Equities

RSLS

US7611236032

Advanced Medical Equipment & Technology

Sales 2024 * 9.99M Sales 2025 * 11.99M Capitalization 4M
Net income 2024 * -6M Net income 2025 * -5M EV / Sales 2024 * 0.4 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.33 x
P/E ratio 2024 *
-0.38 x
P/E ratio 2025 *
-0.47 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.84%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 20-01-31
Director of Finance/CFO 63 21-06-14
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 15-12-31
Chairman 70 15-10-31
Director/Board Member 70 21-06-14
More insiders
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
More about the company